Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIALIS vs CHEWTADZY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Treatment of erectile dysfunction,Treatment of benign prostatic hyperplasia,Treatment of pulmonary arterial hypertension (as Adcirca)
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.
2 mg orally twice daily
The terminal elimination half-life of tadalafil is approximately 17.5 hours in healthy subjects, which supports once-daily dosing for erectile dysfunction and once-daily use for benign prostatic hyperplasia. This long half-life distinguishes it from other PDE5 inhibitors.
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (Cr Cl <30 m L/min)
Primarily hepatic via CYP3A4; minor pathways include CYP2C9 and glucuronidation.
Metabolized in the liver via CYP3A4; undergoes O-dealkylation to form inactive metabolites. Approximately 50% excreted unchanged in urine.
Following oral administration, tadalafil is predominantly eliminated by hepatic metabolism. The metabolites are excreted mainly in feces (approximately 61% of the dose) and to a lesser extent in urine (approximately 36% of the dose). No unchanged parent drug is detected in urine.
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Tadalafil is 94% bound to plasma proteins, primarily to albumin. The protein binding is independent of drug concentration over a wide range.
99% bound primarily to albumin
The apparent volume of distribution (Vd/F) is approximately 63 L (or roughly 0.9 L/kg for a 70 kg individual), indicating distribution into tissues beyond the vascular space, including the penis and other target organs.
0.15-0.25 L/kg, indicating minimal extravascular distribution; low Vd suggests limited tissue penetration
Absolute oral bioavailability of tadalafil has not been formally determined; however, the drug is well absorbed after oral administration, with peak plasma concentrations reached in 0.5 to 6 hours (median 2 hours). Food does not affect the extent of absorption (AUC), though it may delay the rate (Tmax) by about 1–2 hours.
Oral: 85-95% (high, minimal first-pass metabolism); other routes not applicable
Cr Cl 30-50 m L/min: 5 mg once daily (max) for daily use; as-needed dosing: 10 mg not to exceed once every 48 hours. Cr Cl <30 m L/min: not recommended. Hemodialysis: not studied.
GFR 30-79 m L/min: no adjustment; GFR 15-29 m L/min: 2 mg once daily; GFR <15 m L/min: not recommended
Child-Pugh A and B: no dose adjustment necessary for as-needed dosing; daily use: caution, start at 5 mg once daily. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 1 mg twice daily; Child-Pugh C: contraindicated
Not indicated for pediatric patients under 18 years.
0.15 mg/kg/dose orally twice daily; maximum 2 mg per dose
No dose adjustment required solely based on age; consider renal function and concomitant medications.
Initiate at 1 mg twice daily; titrate cautiously to 2 mg twice daily based on response and tolerability
None
None
Risk of hypotension with vasodilators or alpha-blockers,Contraindicated with nitrates due to severe hypotension risk,Patients with left ventricular outflow obstruction (e.g., aortic stenosis) should avoid use,Caution in patients with hypotension, severe hepatic impairment, or end-stage renal disease,Risk of priapism: advise immediate medical attention for erections lasting >4 hours,Decreased visual or hearing ability requiring discontinuation
May cause drowsiness; avoid driving or operating heavy machinery until effects are known,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min), dose adjustment required,Avoid concurrent use with alcohol or other CNS depressants
Concomitant use of nitrates (any form) or riociguat,Hypersensitivity to tadalafil,Concomitant use with alpha-blockers (except for BPH with appropriate dosing)
Hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation,Severe renal impairment (creatinine clearance <10 m L/min)
Avoid high-fat meals prior to dosing as they may delay absorption and reduce peak plasma concentration. Avoid large quantities of grapefruit juice (more than 1 liter per day) as it may increase tadalafil exposure via CYP3A4 inhibition.
Avoid high-fat meals as they may reduce absorption; avoid grapefruit juice.
FDA Pregnancy Category B. Animal studies show no evidence of teratogenicity or embryotoxicity. No adequate, well-controlled studies in pregnant women. Risk cannot be ruled out; use only if clearly needed.
Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.
Excretion in human milk unknown. Not recommended for use in nursing mothers. M/P ratio not determined.
No human data. M/P ratio unknown. Exercise caution; consider alternatives.
No specific dose adjustments studied in pregnancy. Use lowest effective dose if necessary, with caution for increased plasma volume and renal clearance potentially altering pharmacokinetics.
No established dose adjustments in pregnancy. Monitor clinical response and adjust as needed.
Tadalafil (Cialis) has a 17.5-hour half-life allowing once-daily dosing for ED or daily for BPH/LUTS. Avoid use with nitrates; may cause prolonged erection. Onset of action is 30-60 minutes, and effect may last up to 36 hours. Use with caution in patients with left ventricular outflow obstruction or severe hepatic impairment.
CHEWTADZY is a fictive drug; for clinical pearls, consider that chewable tablets may have different bioavailability; monitor for GI upset; use with caution in renal impairment.
Do not take tadalafil if you take any form of nitrate medication (e.g., nitroglycerin) for chest pain.,Seek immediate medical help if you have an erection lasting more than 4 hours.,Avoid alcohol consumption as it may increase the risk of dizziness and low blood pressure.,Take tadalafil at least 30 minutes before sexual activity; effect can last up to 36 hours.,For daily use, take at the same time each day without regard to timing of sexual activity.,Grapefruit and grapefruit juice may increase tadalafil levels; avoid large amounts.,Inform your doctor of all medications you take, especially alpha-blockers, antihypertensives, and antifungal or antibiotic drugs.
Take with food to reduce stomach upset.,Chew or crush tablet completely before swallowing.,Complete full course even if feeling better.,Avoid alcohol while taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIALIS vs CHEWTADZY, answered by our medical review team.
CIALIS is a PDE5 Inhibitor that works by Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.. CHEWTADZY is a PDE5 Inhibitor that works by CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIALIS and CHEWTADZY depend on the specific clinical indication. These are both PDE5 Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIALIS is: Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.. The standard adult dose of CHEWTADZY is: 2 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIALIS and CHEWTADZY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIALIS is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of teratogenicity or embryotoxicity. No adequate, well-controlled studies in pregnant women. Risk cannot be ruled out; use. CHEWTADZY is classified as Category C. Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.